Bukwang Pharmaceutical Co., Ltd. (003000.KS)
KRW 4745.0
(-1.35%)
KRW 4745.0
(-1.35%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 50.04 Billion KRW | -36.99% |
| 2022 | 79.42 Billion KRW | 4.85% |
| 2021 | 75.75 Billion KRW | 5.75% |
| 2020 | 71.64 Billion KRW | -14.96% |
| 2019 | 84.24 Billion KRW | -26.74% |
| 2018 | 115 Billion KRW | 42.64% |
| 2017 | 80.62 Billion KRW | 5.69% |
| 2016 | 76.29 Billion KRW | -7.91% |
| 2015 | 82.84 Billion KRW | 1.98% |
| 2014 | 81.23 Billion KRW | 14.81% |
| 2013 | 70.75 Billion KRW | -11.1% |
| 2012 | 79.59 Billion KRW | 41.48% |
| 2011 | 56.25 Billion KRW | -46.8% |
| 2010 | 105.75 Billion KRW | 7.74% |
| 2009 | 98.15 Billion KRW | 1.91% |
| 2008 | 96.31 Billion KRW | -0.53% |
| 2007 | 96.82 Billion KRW | 25.26% |
| 2006 | 77.3 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | 42.59 Billion KRW | 13.24% |
| 2024 Q1 | 16.45 Billion KRW | -11.05% |
| 2024 Q2 | 17.9 Billion KRW | 8.82% |
| 2023 Q1 | 17.01 Billion KRW | -33.58% |
| 2023 FY | 50.04 Billion KRW | -36.99% |
| 2023 Q2 | 17.31 Billion KRW | 1.73% |
| 2023 Q3 | 6.21 Billion KRW | -64.08% |
| 2023 Q4 | 18.49 Billion KRW | 197.42% |
| 2022 Q2 | 18.75 Billion KRW | 18.52% |
| 2022 Q1 | 15.82 Billion KRW | -29.01% |
| 2022 FY | 79.42 Billion KRW | 4.85% |
| 2022 Q3 | 19.22 Billion KRW | 2.46% |
| 2022 Q4 | 25.62 Billion KRW | 33.29% |
| 2021 FY | 75.75 Billion KRW | 5.75% |
| 2021 Q1 | 16.94 Billion KRW | -20.88% |
| 2021 Q3 | 19.75 Billion KRW | 17.88% |
| 2021 Q2 | 16.76 Billion KRW | -1.06% |
| 2021 Q4 | 22.29 Billion KRW | 12.85% |
| 2020 Q1 | 18 Billion KRW | -32.06% |
| 2020 Q3 | 15.4 Billion KRW | -8.38% |
| 2020 Q4 | 21.41 Billion KRW | 38.98% |
| 2020 Q2 | 16.81 Billion KRW | -6.59% |
| 2020 FY | 71.64 Billion KRW | -14.96% |
| 2019 Q3 | 18.41 Billion KRW | -9.54% |
| 2019 Q4 | 26.49 Billion KRW | 43.86% |
| 2019 Q1 | 18.97 Billion KRW | -11.44% |
| 2019 FY | 84.24 Billion KRW | -26.74% |
| 2019 Q2 | 20.36 Billion KRW | 7.34% |
| 2018 FY | 115 Billion KRW | 42.64% |
| 2018 Q3 | 52.96 Billion KRW | 139.5% |
| 2018 Q4 | 21.42 Billion KRW | -59.55% |
| 2018 Q2 | 22.11 Billion KRW | 19.49% |
| 2018 Q1 | 18.5 Billion KRW | -12.56% |
| 2017 Q3 | 20.23 Billion KRW | -3.92% |
| 2017 Q1 | 18.17 Billion KRW | 0.28% |
| 2017 Q2 | 21.05 Billion KRW | 15.86% |
| 2017 FY | 80.62 Billion KRW | 5.69% |
| 2017 Q4 | 21.16 Billion KRW | 4.61% |
| 2016 Q3 | 18.46 Billion KRW | -11.76% |
| 2016 FY | 76.29 Billion KRW | -7.91% |
| 2016 Q2 | 20.92 Billion KRW | 11.45% |
| 2016 Q4 | 18.12 Billion KRW | -1.85% |
| 2016 Q1 | 18.77 Billion KRW | -16.16% |
| 2015 Q4 | 22.39 Billion KRW | 8.02% |
| 2015 Q2 | 20.54 Billion KRW | 7.19% |
| 2015 FY | 82.84 Billion KRW | 1.98% |
| 2015 Q3 | 20.73 Billion KRW | 0.89% |
| 2015 Q1 | 19.16 Billion KRW | -7.44% |
| 2014 Q4 | 20.7 Billion KRW | 0.76% |
| 2014 Q2 | 19.77 Billion KRW | -2.06% |
| 2014 Q1 | 20.19 Billion KRW | 8.8% |
| 2014 Q3 | 20.55 Billion KRW | 3.92% |
| 2014 FY | 81.23 Billion KRW | 14.81% |
| 2013 Q4 | 18.56 Billion KRW | 3.99% |
| 2013 FY | 70.75 Billion KRW | -11.1% |
| 2013 Q2 | 17.3 Billion KRW | 1.58% |
| 2013 Q1 | 17.03 Billion KRW | -25.38% |
| 2013 Q3 | 17.84 Billion KRW | 3.13% |
| 2012 Q2 | 19.76 Billion KRW | 34.88% |
| 2012 Q3 | 22.51 Billion KRW | 13.95% |
| 2012 FY | 79.59 Billion KRW | 41.48% |
| 2012 Q1 | 14.65 Billion KRW | 0.0% |
| 2012 Q4 | 22.83 Billion KRW | 1.39% |
| 2011 Q3 | 20.43 Billion KRW | -17.38% |
| 2011 Q2 | 24.73 Billion KRW | -20.83% |
| 2011 Q1 | 31.23 Billion KRW | 18.6% |
| 2011 FY | 56.25 Billion KRW | -46.8% |
| 2010 FY | 105.75 Billion KRW | 7.74% |
| 2010 Q3 | 25.94 Billion KRW | 16.72% |
| 2010 Q4 | 26.33 Billion KRW | 1.51% |
| 2010 Q2 | 22.22 Billion KRW | -10.93% |
| 2010 Q1 | 24.95 Billion KRW | 0.92% |
| 2009 Q4 | 24.72 Billion KRW | -1.9% |
| 2009 FY | 98.15 Billion KRW | 1.91% |
| 2009 Q1 | - KRW | -100.0% |
| 2009 Q2 | 23.26 Billion KRW | 0.0% |
| 2009 Q3 | 25.2 Billion KRW | 8.34% |
| 2008 FY | 96.31 Billion KRW | -0.53% |
| 2008 Q2 | 23.87 Billion KRW | 0.0% |
| 2008 Q3 | 24.31 Billion KRW | 1.84% |
| 2008 Q4 | 23.33 Billion KRW | -4.02% |
| 2008 Q1 | - KRW | -100.0% |
| 2007 Q2 | 21.75 Billion KRW | 0.0% |
| 2007 Q4 | 25.97 Billion KRW | 2.79% |
| 2007 FY | 96.82 Billion KRW | 25.26% |
| 2007 Q3 | 25.27 Billion KRW | 16.14% |
| 2006 FY | 77.3 Billion KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -7.613% |
| Dong-A Socio Holdings Co., Ltd. | 364.1 Billion KRW | 86.255% |
| Ildong Holdings Co., Ltd. | 198.88 Billion KRW | 74.837% |
| HANDOK Inc. | 151.36 Billion KRW | 66.938% |
| Kukje Pharma Co., Ltd. | 67.22 Billion KRW | 25.555% |
| Yuhan Corporation | 564.5 Billion KRW | 91.135% |
| Dong-A ST Co., Ltd. | 322.21 Billion KRW | 84.468% |
| SAMSUNG PHARM. Co., LTD. | 23.74 Billion KRW | -110.744% |
| Hanmi Pharm. Co., Ltd. | 835.85 Billion KRW | 94.013% |
| Hanall Biopharma Co.,Ltd | 75.03 Billion KRW | 33.308% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 74.847% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.64 Billion KRW | -23.114% |
| MYUNGMOON Pharm co.,Ltd | 94.51 Billion KRW | 47.05% |
| Hana Pharm Co., Ltd. | 140.85 Billion KRW | 64.47% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -7.613% |
| Ilsung Pharmaceuticals Co., Ltd. | 34.71 Billion KRW | -44.158% |
| REYON Pharmaceutical Co., Ltd. | 76.81 Billion KRW | 34.852% |
| Aprogen pharmaceuticals,Inc. | -12.04 Billion KRW | 515.467% |
| JW Holdings Corporation | 446.15 Billion KRW | 88.783% |
| Ildong Pharmaceutical Co., Ltd. | 207.53 Billion KRW | 75.886% |
| Chong Kun Dang Pharmaceutical Corp. | 655.34 Billion KRW | 92.363% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 85.091% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | 36.345% |
| Hyundai Pharmaceutical Co., Ltd. | 75.23 Billion KRW | 33.484% |
| Samil Pharmaceutical Co.,Ltd | 72.21 Billion KRW | 30.696% |
| Jeil Pharmaceutical Co.,Ltd | 183.81 Billion KRW | 72.774% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -7.613% |
| Kwang Dong Pharmaceutical Co., Ltd. | 295.11 Billion KRW | 83.042% |
| Daewoong pharmaceutical Co.,Ltd | 681.55 Billion KRW | 92.657% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 85.091% |
| Yuhan Corporation | 564.5 Billion KRW | 91.135% |
| Jeil Pharma Holdings Inc | 201.82 Billion KRW | 75.203% |
| Yungjin Pharm. Co., Ltd. | 70.93 Billion KRW | 29.453% |
| Suheung Co., Ltd. | 99.02 Billion KRW | 49.463% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 85.091% |
| Samjin Pharmaceuticals Co., Ltd. | 145.89 Billion KRW | 65.697% |
| Korea United Pharm Inc. | 173.48 Billion KRW | 71.153% |
| CKD Bio Corp. | 5.01 Billion KRW | -898.852% |
| Daewon Pharmaceutical Co., Ltd. | 254.23 Billion KRW | 80.315% |
| Dongwha Pharm.Co.,Ltd | 184.12 Billion KRW | 72.82% |
| Whan In Pharm Co.,Ltd. | 98.12 Billion KRW | 48.998% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | 36.345% |
| Chong Kun Dang Holdings Corp. | 371.49 Billion KRW | 86.529% |
| Boryung Corporation | 333.26 Billion KRW | 84.983% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 74.847% |
| JW Lifescience Corporation | 51.32 Billion KRW | 2.493% |